Indonesia HER-2 Negative Breast Cancer Market Report 2022 to 2030

Indonesia HER-2 Negative Breast Cancer Market Analysis

$ 3999

Indonesia HER-2 Negative Breast Cancer Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 � 2030. A number of factors, such as age, obesity, alcoholism, radiation exposure history, family history of breast cancer, family history of the disease, age at first pregnancy, onset of the menstrual cycle, and tobacco use, increase the risk of developing the disease. As a result of lifestyle changes, the incidence and prevalence of breast cancer are rising quickly. All of this will drive a HER-2 Negative Breast Cancer Market.The global HER-2 Negative Breast Cancer market�s major key players are Pfizer, Novartis AG Merck & Co. Inc., GlasxoSmithKline, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca, Lupin, Bayer AG.

ID: IN10IDPH300 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Dr. Netal Patel

Buy Now

Indonesia HER-2 Negative Breast Cancer Market Analysis Summary

Indonesia HER-2 Negative Breast Cancer Market is valued at around $80.5 Mn in 2022 and is projected to reach $193.5 Mn by 2030, exhibiting a CAGR of 11.6% during the forecast period 2023-2030.

Low levels of malignant cells can be found in breast cancer that tests negative for the HER2 protein. The prognosis varies, even though this type of breast cancer has a wide range of therapeutic choices. "HER2" stands for human epidermal growth factor receptor 2. It can be talking about the HER2 gene or the HER2 protein that the gene generates. Breast cells have receptors called HER2 proteins on their surface. They typically assist in controlling the renewal and proliferation of healthy breast tissue. However, when the HER2 gene develops a malfunction and starts making too many copies of itself, the HER2 proteins are overproduced on the surface of breast cells. HER2-positive cancer could result from this. Radiation therapy, surgery, chemotherapy, hormone or targeted therapy, and immunotherapy may be used to treat HER2-negative breast cancer as well as other types of breast cancer. Several factors, such as age, obesity, alcoholism, radiation exposure history, family history of breast cancer, family history of the disease, age at first pregnancy, onset of the menstrual cycle, and tobacco use, increase the risk of developing the disease. As a result of lifestyle changes, the incidence and prevalence of breast cancer are rising quickly. All of this will drive a HER-2 Negative Breast Cancer Market. The global HER-2 Negative Breast Cancer market’s major key players are Pfizer, Novartis AG Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca, Lupin, Bayer AG.

Market Dynamics

Market Growth Drivers

The Global Cancer Observatory's (Globocan) analysis found that in 2020, breast cancer was the cancer kind that was most common worldwide. In 2020, there will be around 2,261,419 new cases of breast cancer. By 2040, there are expected to be 3,025,471 new cases of breast cancer, up from 2,261,419 in 2020. This study demonstrates that breast cancer is becoming more commonplace throughout the world. The market for HER-2-negative breast cancer is anticipated to expand because of the rising incidence of breast cancer worldwide. The leading competitors in the market are also expanding their product approval and pipeline items due to the industry's expanding R&D efforts, which is expected to impact the segment's growth substantially.

Market Restraints

The market's growth throughout the anticipated time range may be hampered by a lack of experts trained in intracranial stents. Cerebrovascular Complications Related to Intracranial Stenting is another concern that may restrict market expansion.

Competitive Landscape

Key Players

Pfizer
Novartis AG Merck & Co. Inc.
GlaxoSmithKline
Eli Lilly and Company
Bristol Myers Squibb Company
AstraZeneca
Lupin
Bayer AG.

Developments in the HER-2 Negative Breast Cancer Market

In September 2022, in a fresh pooled exploratory analysis spanning the entire MONALEESA Phase III program, Novartis confirmed nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive types of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. (ABC).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Indonesia HER-2 Negative Breast Cancer Market Segmentation

By Treatment Type

Chemotherapy
Radiation
Hormonal Therapy
Other Types of Treatments

By Channel Type

Direct Sales
Distributor

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.